Level B· Emerging clinical evidence with positive signalsRandomized Controlled TrialPubMed

Synergistic Effect of Platelet-Rich Plasma and Stromal Vascular Fraction in Atrophic Acne Scar Management: A Mechanistic and Clinical Pilot RCT.

Abdalla MS., Karras MS., Zohdy M., El-Mongy SE., El Fahar MH.

Randomized Controlled Trial with a reported sample of 60 on Scar, published in Aesthetic Plast Surg (2026) — summary generated from the PubMed abstract.

Open my reading list
Level B· Emerging clinical evidence with positive signalsEvidence level of this study

Several human studies show positive signals, while research methods and sample sizes continue to develop.

  • Level A · Stronger Clinical Evidence
  • Level B · Emerging clinical evidence with positive signals
  • Level C · Early human research exploring benefits
  • Level D · Scientific groundwork from lab and animal studies
  • Emerging · Emerging topic under active research
Read the A–D evidence level guide

This page is generated from the PubMed record. The Thai description is an automated summary of bibliographic fields and the abstract, not a full translation, and is not medical advice.

Study type
Randomized Controlled Trial
Journal
Aesthetic Plast Surg (2026)
Country
United States
Reported sample size
60
Source database
PubMed
PMID
42151612
DOI
10.1007/s00266-026-05871-7

Abstract (original English)

Background Atrophic acne scarring presents a significant therapeutic challenge with a profound psychosocial impact, and conventional treatments often yield suboptimal results. Autologous biologics, specifically stromal vascular fraction (SVF) and platelet-rich plasma (PRP), have emerged as promising regenerative strategies to address this issue. Methods This single-center, pilot, randomized, assessor-blinded controlled trial included 60 patients with severe atrophic acne scars. Patients were randomized into four groups: subcision plus SVF (Group 1), subcision plus combined SVF and PRP (Group 2), subcision plus PRP (Group 3), and subcision alone (Group 4, control). Primary endpoints included clinical improvement documented by digital imaging and changes in qualitative grading scales from baseline to 12 months post-procedure. Additionally, flow cytometry was performed to evaluate the cellular composition and mesenchymal stem cell (MSC) marker expression of the SVF preparations. Results Group 2 (subcision + SVF + PRP) demonstrated superior clinical efficacy, with 53.3% of patients achieving "Grade 3" (marked) physician satisfaction compared to 0% in the control group (p ≤ 0.001). This group also showed significantly greater improvement in scar size and color (p ≤ 0.001). Mechanistically, flow cytometry confirmed that Group 2 contained significantly higher expression of mesenchymal

What this study does not prove

  • • This study does not prove SVF is an approved treatment or a replacement for standard care.

Evidence level

Several human studies show positive signals, while research methods and sample sizes continue to develop.

How we grade evidence
HumansPlatelet-Rich PlasmaCicatrixFemalePilot ProjectsAdultAcne VulgarisMaleYoung AdultAtrophy

Browse all related research

Filter the research library by this study's title keywords, author, or publication year.

Related research